Premature ejaculation (PE) is a common condition that troubles men in today's society, which significantly influences men's mental health and the relationship between spouses. Both traditional Chinese medicine (TCM) and Western medicine are currently the preferred treatment options for PE. When treating PE with both traditional Chinese and Western medicine, two sets of treatment plans are briefly introduced: internal treatment and external treatment. In the internal treatment method, the popular TCM formulas in recent years were introduced, their therapeutic effects and principles on PE were described, and the results of analyzing the effective ingredients of TCM monomers from the perspective of molecular biology in recent years were also presented. Then the mechanism of their treatment of PE was explained and their efficacy and safety was compared with Western medicine in treating PE; in terms of external treatment, the current mainstream treatment schemes were introduced, such as acupuncture and moxibustion, liquid medicine external application, massage desensitization and behavioral psychotherapy, and their advantages and disadvantages were elaborated. Finally, the theoretical treatment of PE was put into practice through rational criticism and analysis to improve men's physical health and promote the development of the TCM culture.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.22514/j.androl.2024.019 | DOI Listing |
Background: Our previous study identified that Sildenafil (a phosphodiesterase type 5 [PDE5] inhibitor) is a candidate repurposable drug for Alzheimer's Disease (AD) using in silico network medicine approach. However, the clinically meaningful size and mechanism-of-actions of sildenafil in potential prevention and treatment of AD remind unknown.
Method: We conducted new patient data analyses using both the MarketScan® Medicare with Supplemental database (n = 7.
Alzheimers Dement
December 2024
National Institute on Aging, NIH, Baltimore, MD, USA.
Background: Epidemiological studies report an elevated risk of neurodegenerative disorders, particularly Parkinson's disease (PD), in patients with type 2 diabetes mellitus (T2DM) that is mitigated in those prescribed incretin mimetics or dipeptidyl peptidase 4 inhibitors (DPP-4Is). Incretin mimetic repurposing appears promising in human PD and Alzheimer's disease (AD) clinical trials. DPP-4Is are yet to be evaluated in PD or AD human studies.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China.
Background: Effective early intervention of mild cognitive impairment (MCI) is the key for preventing dementia. However, there is currently no drug for MCI. As a multi-targeted neuroprotective agent, butylphthalide has been demonstrated to repair cognition in patients with vascular cognitive impairment, and has the potential to treat MCI due to Alzheimer's disease (AD).
View Article and Find Full Text PDFBackground: Seizures in Alzheimer's Disease (AD) are increasingly recognized to occur and can increase cognitive decline and reduce survival compared to unaffected age-matched peers (Lyou et al. 2018). Administration of antiseizure medicines (ASMs) to AD patients with epileptiform activity may improve cognition (Vossel et al.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China.
Background: Cognitive impairment, a common aging-related pathology, is a risk factor for dementia. Echinacoside (ECH), derived from the traditional Chinese medicine Cistanche deserticola, shows anti-aging properties including anti-inflammation, oxidative stress reduction, and neuronal protection. Despite its benefits, the beneficial impact of ECH on age-related cognitive decline remains unclear.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!